DE60205397D1 - 4-(thio- oder selenoxanthen-9-yliden)-piperidin oder acridin derivate und ihre verwendung als selektive 5ht2b rezeptorantagonisten - Google Patents

4-(thio- oder selenoxanthen-9-yliden)-piperidin oder acridin derivate und ihre verwendung als selektive 5ht2b rezeptorantagonisten

Info

Publication number
DE60205397D1
DE60205397D1 DE60205397T DE60205397T DE60205397D1 DE 60205397 D1 DE60205397 D1 DE 60205397D1 DE 60205397 T DE60205397 T DE 60205397T DE 60205397 T DE60205397 T DE 60205397T DE 60205397 D1 DE60205397 D1 DE 60205397D1
Authority
DE
Germany
Prior art keywords
thio
piperidine
selenoxanthen
ylidenes
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60205397T
Other languages
English (en)
Other versions
DE60205397T2 (de
Inventor
Hermann Luebbert
Christoph Ullmer
Emile Bellott
Mark Froimowitz
Douglas Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofrontera Bioscience GmbH
Original Assignee
Biofrontera Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Pharmaceuticals GmbH filed Critical Biofrontera Pharmaceuticals GmbH
Application granted granted Critical
Publication of DE60205397D1 publication Critical patent/DE60205397D1/de
Publication of DE60205397T2 publication Critical patent/DE60205397T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60205397T 2001-10-25 2002-10-23 4-(thio- oder selenoxanthen-9-yliden)-piperidin oder acridin derivate und ihre verwendung als selektive 5ht2b rezeptorantagonisten Expired - Lifetime DE60205397T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01125527 2001-10-25
EP01125527A EP1306376A1 (de) 2001-10-25 2001-10-25 Derivaten von 4-(Thio- oder Selenoxanthen-9-yliden)-Piperidin oder Acridine und ihre Verwendung als selektieven 5-HT2B antagonisten
PCT/EP2002/011817 WO2003035646A2 (en) 2001-10-25 2002-10-23 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist

Publications (2)

Publication Number Publication Date
DE60205397D1 true DE60205397D1 (de) 2005-09-08
DE60205397T2 DE60205397T2 (de) 2006-05-24

Family

ID=8179078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205397T Expired - Lifetime DE60205397T2 (de) 2001-10-25 2002-10-23 4-(thio- oder selenoxanthen-9-yliden)-piperidin oder acridin derivate und ihre verwendung als selektive 5ht2b rezeptorantagonisten

Country Status (14)

Country Link
EP (2) EP1306376A1 (de)
JP (1) JP4452501B2 (de)
KR (1) KR100921214B1 (de)
CN (1) CN100345843C (de)
AT (1) ATE301119T1 (de)
AU (1) AU2002350603B2 (de)
CA (1) CA2462416C (de)
DE (1) DE60205397T2 (de)
DK (1) DK1438307T3 (de)
ES (1) ES2246416T3 (de)
HK (1) HK1073311A1 (de)
RU (1) RU2314305C2 (de)
WO (1) WO2003035646A2 (de)
ZA (1) ZA200403095B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004057338A1 (en) * 2002-12-23 2004-07-08 Bayer Healthcare Ag Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)
BRPI0411998A (pt) * 2003-06-27 2006-09-05 Janssen Pharmaceutica Nv moduladores delta-opióides tricìclicos
WO2007030089A1 (en) 2004-08-05 2007-03-15 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
US7439239B2 (en) 2004-12-22 2008-10-21 Janssen Pharmaceutica N.V. Tricyclic δ- opioid modulators
BRPI0519201A2 (pt) 2004-12-22 2008-12-30 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclico
CN101128460A (zh) 2005-01-06 2008-02-20 詹森药业有限公司 三环的δ-阿片样物质调节剂
WO2006138528A2 (en) 2005-06-16 2006-12-28 Janssen Pharmaceutica N.V Tricyclic opioid modulators
WO2008124184A1 (en) * 2007-04-09 2008-10-16 Xvasive Inc. Treatment of headaches, neck pain, joint pain and inflammatory-type pain
WO2014117863A1 (en) 2013-02-01 2014-08-07 Biofrontera Bioscience Gmbh Salt polymorph of thioxanthene - 9 - ylidene - 1 - methyl piperidine acid addition salts as antimigraine compounds
KR102105682B1 (ko) 2018-08-29 2020-04-28 성균관대학교산학협력단 신규 2-아실 아크리딘 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122808C (de) * 1961-09-29
NL301204A (de) * 1962-12-07
NL6818027A (de) * 1968-01-09 1969-07-11
BE791699A (fr) * 1971-11-22 1973-05-21 Sandoz Sa Nouveaux derives du thioxanthene, leur preparation et leur application comme medicaments
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
ZA756550B (en) * 1974-11-06 1976-09-29 Smithkline Corp Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms
US4285956A (en) * 1978-05-12 1981-08-25 Kefalas A/S Xanthene and thioxanthene derivatives, compositions thereof and treatment therewith
US4777177A (en) * 1984-10-19 1988-10-11 Ciba-Geigy Corporation Pesticidal thioxanthen-9-ylidenepiperidines

Also Published As

Publication number Publication date
RU2004116070A (ru) 2005-11-10
WO2003035646A2 (en) 2003-05-01
CA2462416C (en) 2011-04-26
ATE301119T1 (de) 2005-08-15
DK1438307T3 (da) 2005-12-12
JP2005510504A (ja) 2005-04-21
CA2462416A1 (en) 2003-05-01
ZA200403095B (en) 2005-01-25
EP1306376A1 (de) 2003-05-02
KR100921214B1 (ko) 2009-10-09
DE60205397T2 (de) 2006-05-24
AU2002350603B2 (en) 2008-02-28
CN100345843C (zh) 2007-10-31
RU2314305C2 (ru) 2008-01-10
WO2003035646A3 (en) 2003-09-04
HK1073311A1 (en) 2005-09-30
JP4452501B2 (ja) 2010-04-21
CN1575291A (zh) 2005-02-02
KR20040047982A (ko) 2004-06-05
EP1438307B1 (de) 2005-08-03
EP1438307A2 (de) 2004-07-21
ES2246416T3 (es) 2006-02-16

Similar Documents

Publication Publication Date Title
HK1073311A1 (en) Derivatives of 4-(thioxanthene-9-ylidene)-piperid ine or acridine and its use in the manufacture of a medicament
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
ATE428422T1 (de) Piperidin-derivate als ccr3-antagonisten
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
ATE414516T1 (de) Morphinanderivate als mittel gegen juckreiz
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
WO2004054973A3 (en) Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
RU2008110945A (ru) N-оксиды как пролекарства производных пиперазина и пиперидина
ATE499366T1 (de) 1-ä(6-substituiertes alkoxychinoxalinyl)
DE60326933D1 (de) Kondensierte bicyclische pyrimidinderivate
DE602006017849D1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors
BR0308844A (pt) Derivado de pirimidina bicìclica fundida e seus sais farmaceuticamente aceitáveis que atuam como antagonistas do receptor de taquicinina, bem como, as aplicações médicas desses compostos
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
DE602005022698D1 (de) Alkaloidverbindungen und ihre verwendung als antimalariamittel
BR0317363A (pt) Antagonista de npy-5

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOFRONTERA BIOSCIENCE GMBH, 51377 LEVERKUSEN, DE